Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
2
×
boston
boston blog main
boston top stories
clinical trials
fda
2
×
life sciences
national blog main
avapritinib
biotech ipos
blueprint medicines
cstone pharmaceuticals
deals
dyne therapeutics
eli lilly
european medicines agency
fisogatinib
flatiron health
genentech
hepatocellular carcinoma
investing
jeff albers
medullary thyroid cancer
metacrine
myotonic dystrophy type 1
national top stories
non-small cell lung cancer
nonalcoholic steatohepatitis
pralsetinib
rare disease drugs
rare diseases
roche
salk institute
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
selpercatinib
thermo fisher scientific
thyroid cancer
What
drug
medicines
muscle
2
×
approval
blueprint
brings
cancer
candidate
company
currently
developing
disorders
dyne
dyne’s
fda
genetic
ipo
marketing
million
muscular
pact
preclinical
raised
rare
regulatory
ret
review
roche
stage
team
therapeutics
topped
upsized
wins
Language
unset
Current search:
muscle
×
biotech
×
fda
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
